

Xavier Matias-Guiu Guia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5842127/publications.pdf>

Version: 2024-02-01

335
papers

17,367
citations

13099

68
h-index

22832

112
g-index

347
all docs

347
docs citations

347
times ranked

19340
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	5.9	9
2	Comparison of the Idylla [®] , [®] MSI assay with the Promega [®] , [®] MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1031-1039.	2.8	6
3	<i>ARID1A</i> deficient cells require HDAC6 for progression of endometrial carcinoma. <i>Molecular Oncology</i> , 2022, 16, 2235-2259.	4.6	9
4	DigiPatICS: Digital Pathology Transformation of the Catalan Health Institute Network of 8 Hospitals – Planification, Implementation, and Preliminary Results. <i>Diagnostics</i> , 2022, 12, 852.	2.6	12
5	Impact of the COVID-19 pandemic on pathology training: a survey among Spanish residents. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 505-509.	2.8	3
6	Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. <i>Cancers</i> , 2022, 14, 2842.	3.7	6
7	An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide) Tj ETQq1 1 0.784314 rgBT /Overl	2.5	6
8	Facts and Hopes in Immunotherapy of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4849-4860.	7.0	16
9	Autophagy in the physiological endometrium and cancer. <i>Autophagy</i> , 2021, 17, 1077-1095.	9.1	100
10	Multi-center real-world comparison of the fully automated Idylla [®] , [®] microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 851-863.	2.8	23
11	Predicting the rising incidence and mortality of endometrial cancers among women aged 65-74 years in Catalonia. <i>Maturitas</i> , 2021, 144, 11-15.	2.4	2
12	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. <i>Modern Pathology</i> , 2021, 34, 994-1007.	5.5	19
13	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.	2.0	22
14	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.6	96
15	Relevance of pathologic features in risk stratification for early-stage endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e67.	2.2	1
16	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190.	2.8	99
17	Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. <i>Modern Pathology</i> , 2021, 34, 1194-1202.	5.5	24
18	The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. <i>International Journal of Gynecological Pathology</i> , 2021, 40, S102-S110.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with) Tj ETQq1 Gynecological Cancer, 2021, 31, ijgc-2021-002668.	1 0.784314 2.5	rgBT /Ove 2
20	Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes. Journal of Personalized Medicine, 2021, 11, 331.	2.5	2
21	Understanding the Molecular Mechanism of miR-877-3p Could Provide Potential Biomarkers and Therapeutic Targets in Squamous Cell Carcinoma of the Cervix. Cancers, 2021, 13, 1739.	3.7	4
22	M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. Gynecologic Oncology, 2021, 161, 681-686.	1.4	5
23	Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Frontiers in Cell and Developmental Biology, 2021, 9, 670185.	3.7	5
24	SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications, 2021, 12, 4319.	12.8	22
25	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. Gynecologic Oncology, 2021, 163, 14-21.	1.4	6
26	Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancerâ€“Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. Journal of Molecular Diagnostics, 2021, 23, 1452-1459.	2.8	10
27	Sensitivity of cervical cytology in endometrial cancer detection in a tertiary hospital in Spain. Cancer Medicine, 2021, 10, 6762-6766.	2.8	6
28	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
29	BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics. Cancers, 2021, 13, 5073.	3.7	2
30	Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation. Cancers, 2021, 13, 4990.	3.7	13
31	Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification. Acta Dermato-Venereologica, 2021, 101, adv00597.	1.3	4
32	Clonal relationship in multisited mucosaâ€“associated lymphoid tissue lymphomas: a singleâ€“centre experience. British Journal of Haematology, 2021, 192, 1020-1025.	2.5	1
33	912â€“...Preferential recognition of neoantigens over non-canonical peptides in cancer patients. , 2021, 9, A958-A958.		0
34	61â€“...Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in endometrial cancer. , 2021, 9, A69-A69.		0
35	Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligationâ€“dependent probe amplification: a descriptive study. Histopathology, 2020, 76, 447-460.	2.9	8
36	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. Journal of Investigative Dermatology, 2020, 140, 1253-1265.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Clinicopathological and molecular characterisation of "multiple" classifier™ endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	4.5	205
38	Complete Loss of EPCAM Immunoeexpression Identifies EPCAM Deletion Carriers in MSH2-Negative Colorectal Neoplasia. <i>Cancers</i> , 2020, 12, 2803.	3.7	4
39	WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. <i>Nature Communications</i> , 2020, 11, 5315.	12.8	59
40	An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study. <i>Gynecologic Oncology</i> , 2020, 159, 721-731.	1.4	14
41	Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals. <i>Cancers</i> , 2020, 12, 1799.	3.7	15
42	Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. <i>Cancers</i> , 2020, 12, 3419.	3.7	11
43	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 3304.	3.7	5
44	Role of POLE and POLD1 in familial cancer. <i>Genetics in Medicine</i> , 2020, 22, 2089-2100.	2.4	76
45	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , 2020, 17, e1003111.	8.4	25
46	Biomimetic device and foreign body reaction cooperate for efficient tumour cell capture in murine advanced ovarian cancer. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	2
47	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. <i>Modern Pathology</i> , 2020, 33, 1606-1617.	5.5	38
48	Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2125.	4.1	13
49	Sensitivity of cervico-vaginal cytology in endometrial carcinoma: A systematic review and meta-analysis. <i>Cancer Cytopathology</i> , 2020, 128, 792-802.	2.4	23
50	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11217.	6.9	37
51	The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 491-497.	2.8	20
52	The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 489-490.	2.8	2
53	Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study. <i>International Journal of Cancer</i> , 2020, 147, 277-284.	5.1	15
54	Clinical performance evaluation of the Idylla, EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer. <i>BMC Cancer</i> , 2020, 20, 275.	2.6	15

#	ARTICLE	IF	CITATIONS
55	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer. <i>Cancers</i> , 2020, 12, 2751.	3.7	12
56	Endometrial Glandular Neoplasia. , 2020, , 333-406.		0
57	CTCsâ€derived xenograft development in a triple negative breast cancer case. <i>International Journal of Cancer</i> , 2019, 144, 2254-2265.	5.1	31
58	The International Society of Gynecological Pathologists (ISGYP) Endometrial Carcinoma Project. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S1-S2.	1.4	10
59	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. <i>Oncogene</i> , 2019, 38, 6035-6050.	5.9	49
60	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. <i>Scientific Reports</i> , 2019, 9, 15057.	3.3	31
61	Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. <i>Cell</i> , 2019, 176, 757-774.e23.	28.9	117
62	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. <i>Histopathology</i> , 2019, 75, 4-19.	2.9	8
63	Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 585-598.	2.8	17
64	The ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in human endometrium: a novel marker of basal stroma and mesenchymal stem cells. <i>Purinergic Signalling</i> , 2019, 15, 225-236.	2.2	16
65	EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer. <i>Cancers</i> , 2019, 11, 839.	3.7	27
66	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2019, 89, 90-98.	2.0	5
67	EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 208.	4.4	30
68	Defining a mutational signature for endometrial cancer screening and early detection. <i>Cancer Epidemiology</i> , 2019, 61, 129-132.	1.9	7
69	New perspectives on screening and early detection of endometrial cancer. <i>International Journal of Cancer</i> , 2019, 145, 3194-3206.	5.1	58
70	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , 2019, 120, 1037-1044.	6.4	10
71	Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S25-S39.	1.4	51
72	Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). <i>International Journal of Gynecological Pathology</i> , 2019, 38, S93-S113.	1.4	99

#	ARTICLE	IF	CITATIONS
73	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 425-435.	1.4	30
74	Magnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study results. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1175-1181.	1.0	7
75	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S40-S63.	1.4	164
76	Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S64-S74.	1.4	192
77	Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S9-S24.	1.4	54
78	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	16.8	99
79	Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S3-S8.	1.4	4
80	Ovarian neuroendocrine carcinoma of metastatic origin: clues for diagnosis. <i>Human Pathology</i> , 2019, 85, 309-312.	2.0	5
81	Tumor suppressive function of E2F α 1 on PTEN α -induced serrated colorectal carcinogenesis. <i>Journal of Pathology</i> , 2019, 247, 72-85.	4.5	5
82	Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S75-S92.	1.4	48
83	Proteomic Characterization of Epithelial-Like Extracellular Vesicles in Advanced Endometrial Cancer. <i>Journal of Proteome Research</i> , 2019, 18, 1043-1053.	3.7	16
84	Digital quantification of KI-67 in breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 169-176.	2.8	14
85	Novel <i>POLE</i> pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. <i>Human Mutation</i> , 2019, 40, 36-41.	2.5	21
86	International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S114-S122.	1.4	52
87	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018, 42, 561-568.	3.7	214
88	ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1216-1229.	2.4	75
89	α -type calcium channels drive migration/invasion in <i>BRAFV600E</i> melanoma cells through Snail1. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 484-495.	3.3	23
90	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 514-523.	2.5	43

#	ARTICLE	IF	CITATIONS
91	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 885-896.	2.8	39
92	Characterization of ecto-nucleotidases in human oviducts with an improved approach simultaneously identifying protein expression and in situ enzyme activity. <i>Histochemistry and Cell Biology</i> , 2018, 149, 269-276.	1.7	12
93	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. <i>Pathobiology</i> , 2018, 85, 35-40.	3.8	26
94	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	5.1	59
95	SEOM clinical guidelines for endometrial cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 29-37.	2.4	27
96	Endometriosis-associated ovarian neoplasia. <i>Pathology</i> , 2018, 50, 190-204.	0.6	113
97	Advances in endometrial cancer protein biomarkers for use in the clinic. <i>Expert Review of Proteomics</i> , 2018, 15, 81-99.	3.0	20
98	Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12794.	1.2	8
99	Germ cell tumour growth patterns originating from clear cell carcinomas of the ovary and endometrium: a comparative immunohistochemical study favouring their origin from somatic stem cells. <i>Histopathology</i> , 2018, 72, 634-647.	2.9	48
100	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 532-543.	4.1	28
101	Multifocal granular cell tumour of the biliary tree. <i>BMJ Case Reports</i> , 2018, 11, e226352.	0.5	3
102	Can the classification of low-grade endometrial stromal tumors still be improved?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 663-664.	2.8	2
103	Patient-Derived Xenograft Models for Endometrial Cancer Research. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2431.	4.1	32
104	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. <i>Autophagy</i> , 2017, 13, 608-624.	9.1	65
105	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. <i>Cancer</i> , 2017, 123, 3261-3268.	4.1	72
106	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	1.6	53
107	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF- β 2 in mouse endometrium. <i>Cell Death and Differentiation</i> , 2017, 24, 1443-1458.	11.2	24
108	Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias. <i>Journal of Pathology</i> , 2017, 242, 152-164.	4.5	25

#	ARTICLE	IF	CITATIONS
109	Molecular approaches for classifying endometrial carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 200-207.	1.4	137
110	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 1551-1563.	5.1	30
111	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7232-7241.	7.0	37
112	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. <i>Scientific Reports</i> , 2017, 7, 8803.	3.3	30
113	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 6458-6467.	7.0	50
114	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	2.8	63
115	APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions. <i>Thyroid</i> , 2017, 27, 59-66.	4.5	4
116	Reproducibility of measurement of myometrial invasion in endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 63-68.	2.8	11
117	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. <i>Modern Pathology</i> , 2017, 30, 134-145.	5.5	36
118	Activated leukocyte cell adhesion molecule (<scp>ALCAM</scp>) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , 2017, 241, 475-487.	4.5	42
119	Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in <i>RET</i>M918T Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 1334-1345.	7.0	34
120	TGFÎ² Controls Ovarian Cancer Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1658.	4.1	26
121	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. <i>Oncotarget</i> , 2017, 8, 109018-109026.	1.8	12
122	Molecular and clinicopathological classification of high risk endometrial cancer (EC) treated with concurrent chemoradiation therapy (CCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e17110-e17110.	1.6	0
123	The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17070-e17070.	1.6	0
124	Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases. <i>Histology and Histopathology</i> , 2017, 32, 909-915.	0.7	1
125	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. <i>Farmacia Hospitalaria</i> , 2017, 41, 688-691.	0.6	3
126	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 569-576.	3.7	75

#	ARTICLE	IF	CITATIONS
127	2-phenylethanesulphonamide (PFT ^{1/4}) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 352-371.	3.3	11
128	Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. <i>Blood</i> , 2016, 127, 1907-1911.	1.4	7
129	Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. <i>British Journal of Cancer</i> , 2016, 115, 929-939.	6.4	28
130	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 1390-1398.	5.5	80
131	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. <i>British Journal of Cancer</i> , 2016, 115, 716-724.	6.4	76
132	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1386-1395.	10.7	357
133	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , 2016, 10, 137-149.	6.1	34
134	Molecularly determined total tumour load in lymph nodes of stage II colon cancer patients correlates with high-risk factors. A multicentre prospective study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 385-394.	2.8	24
135	Immunotherapy in Endometrial Cancer: In the Nick of Time. <i>Clinical Cancer Research</i> , 2016, 22, 5623-5625.	7.0	28
136	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. <i>European Journal of Cancer</i> , 2016, 63, 74-87.	2.8	13
137	Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols. <i>Journal of Translational Medicine</i> , 2016, 14, 180.	4.4	64
138	Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 526-535.	3.8	6
139	Sprouty1 haploinsufficiency accelerates pheochromocytoma development in Pten+/- mice. <i>Endocrine-Related Cancer</i> , 2016, 23, L7-L11.	3.1	2
140	Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid. <i>Human Pathology</i> , 2016, 48, 132-141.	2.0	20
141	Practical issues in the diagnosis of serous carcinoma of the endometrium. <i>Modern Pathology</i> , 2016, 29, S45-S58.	5.5	37
142	Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF- κ B Pathway in Endometrial Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 545-556.	2.6	9
143	Neuroendocrine Neoplasms, Olfactory Neuroblastomas and Paragangliomas of the Head and Neck. , 2016, , 515-538.		4
144	The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. <i>PLoS ONE</i> , 2016, 11, e0166741.	2.5	18

#	ARTICLE	IF	CITATIONS
145	Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism. <i>Oncotarget</i> , 2016, 7, 52364-52374.	1.8	17
146	Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. <i>Oncotarget</i> , 2016, 7, 53102-53115.	1.8	24
147	Quantification of Unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples. <i>Oncotarget</i> , 2016, 7, 10536-10546.	1.8	14
148	Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer. <i>Oncotarget</i> , 2016, 7, 26979-26991.	1.8	39
149	Annexin A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , 2015, 136, 1863-1873.	5.1	39
150	CD45 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. <i>Respirology</i> , 2015, 20, 831-833.	2.3	9
151	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	5.5	176
152	Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 467-478.	3.3	40
153	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv427.	6.3	164
154	Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model. <i>Methods</i> , 2015, 77-78, 31-40.	3.8	12
155	MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors. <i>Modern Pathology</i> , 2015, 28, 748-757.	5.5	52
156	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015, 28, 1101-1122.	5.5	164
157	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 415-422.	2.8	34
158	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , 2015, 28, 1492-1503.	5.5	23
159	Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. <i>Journal of Medical Genetics</i> , 2015, 52, 647-656.	3.2	102
160	TGF- β -Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. <i>Current Biology</i> , 2015, 25, 2899-2914.	3.9	106
161	Genomic landscape of anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6033-6033.	1.6	0
162	Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12532-e12532.	1.6	1

#	ARTICLE	IF	CITATIONS
163	Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. <i>Epigenetics</i> , 2014, 9, 829-833.	2.7	62
164	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014, 13, 223.	19.2	88
165	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. <i>Science Signaling</i> , 2014, 7, pe15.	3.6	50
166	FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA. <i>Histopathology</i> , 2014, 65, 371-388.	2.9	3
167	MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. <i>Cancer Letters</i> , 2014, 347, 75-78.	7.2	79
168	Prognostic biomarkers in endometrial and ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 315-331.	2.8	43
169	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. <i>Human Pathology</i> , 2014, 45, 522-532.	2.0	36
170	DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. <i>International Journal of Cancer</i> , 2014, 135, 598-610.	5.1	66
171	Stromal signatures in endometrioid endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 631-639.	5.5	23
172	Medullary Thyroid Carcinoma: a 25-Year Perspective. <i>Endocrine Pathology</i> , 2014, 25, 21-29.	9.0	37
173	Tenosynovitis with rice body formation presenting as a cutaneous abscess. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 602-605.	1.3	2
174	ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. <i>Carcinogenesis</i> , 2014, 35, 2679-2686.	2.8	30
175	Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma. <i>Laboratory Investigation</i> , 2014, 94, 608-622.	3.7	27
176	Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 776-787.	4.1	12
177	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. <i>Human Pathology</i> , 2014, 45, 2394-2403.	2.0	18
178	Prognostic value of c-FLIPL/s, HIF-1 α , and NF- κ B ² in stage II and III rectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 645-654.	2.8	8
179	MicroRNAs as prognostic markers in ovarian cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 390, 73-84.	3.2	30
180	Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation. <i>PLoS ONE</i> , 2014, 9, e92764.	2.5	3

#	ARTICLE	IF	CITATIONS
181	Recurrent Amyloid Material in Grafts Used in Patients with Lattice Corneal Dystrophy 2 (Meretoja's) Tj ETQq1 1 0.784314 rgBT /Overl	0.2	2
182	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. American Journal of Pathology, 2013, 182, 350-362.	3.8	35
183	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Human Pathology, 2013, 44, 244-254.	2.0	30
184	Oncogene alterations in endometrial carcinosarcomas. Human Pathology, 2013, 44, 852-859.	2.0	27
185	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Human Pathology, 2013, 44, 1973-1981.	2.0	87
186	Usefulness of Negative and Weak Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas. Endocrine Pathology, 2013, 24, 199-205.	9.0	42
187	Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors. Cancer Research, 2013, 73, 395-405.	0.9	69
188	Long-Term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplastic Growth. American Journal of Pathology, 2013, 183, 277-287.	3.8	22
189	Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. Molecular Oncology, 2013, 7, 763-775.	4.6	16
190	Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 154-167.	4.4	113
191	Molecular pathology of endometrial carcinoma. Histopathology, 2013, 62, 111-123.	2.9	167
192	Plurality of opinion, scientific discourse and pseudoscience: an in depth analysis of the SÃ©ralini et al. study claiming that Roundup, Ready corn or the herbicide Roundup cause cancer in rats. Transgenic Research, 2013, 22, 255-267.	2.4	55
193	BRCA1 loss activates cathepsin-mediated degradation of 53BP1 in breast cancer cells. Journal of Cell Biology, 2013, 200, 187-202.	5.2	71
194	DNA Methylation Signatures Identify Biologically Distinct Thyroid Cancer Subtypes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2811-2821.	3.6	100
195	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Modern Pathology, 2013, 26, 1514-1524.	5.5	68
196	Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin. Human Pathology, 2013, 44, 20-28.	2.0	6
197	An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. DMM Disease Models and Mechanisms, 2013, 6, 710-20.	2.4	38
198	Redefining Stage I Endometrial Cancer: Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment. International Journal of Gynecological Cancer, 2013, 23, 1620-1628.	2.5	25

#	ARTICLE	IF	CITATIONS
199	T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 874-885.	3.3	57
200	Three-dimensional epithelial cultures: a tool to model cancer development and progression. <i>Histology and Histopathology</i> , 2013, 28, 1245-56.	0.7	10
201	A novel molecular tool for lymph node upstaging in colon cancer patients: Results of a prospective European, multicenter study. <i>Journal of Clinical Oncology</i> , 2013, 31, 464-464.	1.6	0
202	ER α -mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNF α and IL1 α in lumen formation and maintenance. <i>Journal of Cell Science</i> , 2012, 125, 1929-44.	2.0	11
203	Mice fed on a diet enriched with genetically engineered multivitamin corn show no subacute toxic effects and no subchronic toxicity. <i>Plant Biotechnology Journal</i> , 2012, 10, 1026-1034.	8.3	15
204	Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. <i>Human Pathology</i> , 2012, 43, 632-643.	2.0	75
205	Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results. <i>Human Pathology</i> , 2012, 43, 1103-1112.	2.0	21
206	Blockade of NF κ B activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. <i>Molecular Oncology</i> , 2012, 6, 530-541.	4.6	29
207	The EMT signaling pathways in endometrial carcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 715-720.	2.4	95
208	Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 569-575.	2.8	37
209	Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia. <i>Histopathology</i> , 2012, 60, 460-471.	2.9	12
210	Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. <i>Molecular and Cellular Endocrinology</i> , 2012, 358, 244-255.	3.2	54
211	Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. <i>International Journal of Cancer</i> , 2012, 130, 967-978.	5.1	35
212	ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. <i>International Journal of Cancer</i> , 2012, 130, 1532-1543.	5.1	50
213	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. <i>American Journal of Pathology</i> , 2011, 178, 1529-1543.	3.8	30
214	Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. <i>Human Pathology</i> , 2011, 42, 185-193.	2.0	38
215	Stem Cells in Human Endometrium and Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 317-327.	1.4	26
216	Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. <i>Histopathology</i> , 2011, 58, 863-869.	2.9	63

#	ARTICLE	IF	CITATIONS
217	Nuclear factor- β 2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1 α independent manner. <i>Laboratory Investigation</i> , 2011, 91, 859-871.	3.7	33
218	MicroRNA signature of the epithelial \rightarrow mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , 2011, 223, 72-80.	4.5	194
219	FGFR2 alterations in endometrial carcinoma. <i>Modern Pathology</i> , 2011, 24, 1500-1510.	5.5	63
220	DcR1 expression in endometrial carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 39-44.	2.8	11
221	Pulmonary Small Cell Carcinoma Metastatic to the Ovary: A Clinicopathologic Study of One Case with Emphasis on the Importance of P53 Analysis in Diagnosis. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 87-90.	1.6	9
222	Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. <i>Endocrine-Related Cancer</i> , 2010, 17, 7-16.	3.1	108
223	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. <i>American Journal of Pathology</i> , 2010, 176, 2722-2731.	3.8	46
224	Endometrioid carcinoma of the endometrium: pathologic and molecular features. <i>Seminars in Diagnostic Pathology</i> , 2010, 27, 226-240.	1.5	31
225	Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1701-1705.	3.6	120
226	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. <i>PLoS Genetics</i> , 2009, 5, e1000637.	3.5	140
227	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. <i>Journal of Proteome Research</i> , 2009, 8, 4676-4684.	3.7	22
228	CK2 β Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. <i>American Journal of Pathology</i> , 2009, 174, 287-296.	3.8	42
229	A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. , 2009, 31, 217-26.		6
230	Metastatic Small Cell Carcinoma to the Thyroid Gland: a Pathologic and Molecular Study Demonstrating the Origin in the Urinary Bladder. <i>Endocrine Pathology</i> , 2008, 19, 190-196.	9.0	12
231	Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. <i>Modern Pathology</i> , 2008, 21, 691-699.	5.5	71
232	Nuclear factor- β activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. <i>Human Pathology</i> , 2008, 39, 994-1001.	2.0	25
233	Targeted therapies in gynecologic cancers and melanoma. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 262-273.	1.5	8
234	Loss of Heterozygosity in Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 305-317.	1.4	18

#	ARTICLE	IF	CITATIONS
235	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 115-124.	1.4	51
236	Pleomorphic Adenoma With Extensive Myoepithelial Component (Myoepithelioma) of the Lower Eyelid. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 223-225.	0.8	10
237	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 628-638.	6.3	769
238	Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-up. <i>Archives of Dermatology</i> , 2007, 143, 266-8.	1.4	52
239	PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. <i>Human Pathology</i> , 2006, 37, 1465-1472.	2.0	134
240	Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. <i>Melanoma Research</i> , 2006, 16, 127-135.	1.2	14
241	Proteasome Inhibitors Induce Death but Activate NF- κ B on Endometrial Carcinoma Cell Lines and Primary Culture Explants. <i>Journal of Biological Chemistry</i> , 2006, 281, 22118-22130.	3.4	94
242	Survivin Expression in Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2005, 24, 247-253.	1.4	62
243	Mutation Analysis of the SDHD Gene in Four Kindreds with Familial Paraganglioma. <i>Diagnostic Molecular Pathology</i> , 2005, 14, 109-114.	2.1	13
244	FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. <i>Laboratory Investigation</i> , 2005, 85, 885-894.	3.7	59
245	Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. <i>Modern Pathology</i> , 2005, 18, 719-727.	5.5	110
246	NF- κ B in development and progression of human cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 475-482.	2.8	926
247	Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the β -catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. <i>Human Pathology</i> , 2005, 36, 605-619.	2.0	121
248	Malignant Peripheral Nerve Sheath Tumor of the Thyroid: A Clinicopathological and Ultrastructural Study of One Case. <i>Endocrine Pathology</i> , 2004, 15, 167-174.	9.0	13
249	Abnormalities in the NF- κ B family and related proteins in endometrial carcinoma. <i>Journal of Pathology</i> , 2004, 204, 569-577.	4.5	101
250	Abnormalities of E- and P-cadherin and catenin (β -, γ -catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. <i>Journal of Pathology</i> , 2003, 199, 471-478.	4.5	121
251	Cyclin D1 gene (CCND1) mutations in endometrial cancer. <i>Oncogene</i> , 2003, 22, 6115-6118.	5.9	107
252	Molecular pathology of atypical polypoid adenomyoma of the uterus. <i>Human Pathology</i> , 2003, 34, 784-788.	2.0	35

#	ARTICLE	IF	CITATIONS
253	Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. <i>Cancer Research</i> , 2003, 63, 5697-702.	0.9	119
254	Malignant Mullerian Mixed Tumor Arising From Ovarian Serous Carcinoma: A Clinicopathologic and Molecular Study of Two Cases. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 268-272.	1.4	42
255	Clonality Analysis in Synchronous or Metachronous Tumors of the Female Genital Tract. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 205-211.	1.4	43
256	CTNNB1 mutations and β -catenin expression in endometrial carcinomas. <i>Human Pathology</i> , 2002, 33, 206-212.	2.0	130
257	Focal myositis of the thigh: unusual MR pattern. <i>Skeletal Radiology</i> , 2002, 31, 307-310.	2.0	16
258	Microsatellite instability and immunostaining for MSH2 and MLH1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 415-420.	1.3	72
259	PTEN Mutations in Eight Spanish Families and One Brazilian Family with Cowden Syndrome. <i>Journal of Investigative Dermatology</i> , 2002, 118, 639-644.	0.7	23
260	Abnormalities of the APC/ β -catenin pathway in endometrial cancer. <i>Oncogene</i> , 2002, 21, 7981-7990.	5.9	252
261	Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 599-604.	2.8	42
262	Molecular pathology of endometrial hyperplasia and carcinoma. <i>Human Pathology</i> , 2001, 32, 569-577.	2.0	278
263	Loss of Heterozygosity at the RB-1 Locus and pRB Immunostaining in Epithelial Ovarian Tumors: A Molecular, Immunohistochemical, and Clinicopathologic Study. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 335-340.	1.4	22
264	Solitary Fibrous Tumor of the Thyroid Gland. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1424-1428.	3.7	90
265	β - And β -catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 464-469.	2.8	52
266	Postirradiation multiple minute digitate porokeratosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 126-130.	1.2	19
267	Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. <i>Journal of Pathology</i> , 2001, 194, 358-366.	4.5	65
268	Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. <i>Cancer</i> , 2001, 92, 787-795.	4.1	44
269	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. <i>Cancer</i> , 2001, 92, 2829-2836.	4.1	103
270	K-ras mutations in endometrial carcinomas with microsatellite instability. <i>Journal of Pathology</i> , 2001, 193, 193-199.	4.5	115

#	ARTICLE	IF	CITATIONS
271	Paucicellular Variant of Anaplastic Thyroid Carcinoma: Report of Two Cases. <i>Endocrine Pathology</i> , 2001, 12, 157-162.	9.0	26
272	K-ras mutations in endometrial carcinomas with microsatellite instability. , 2001, 193, 193.		1
273	Merkel Cell Carcinoma Developing after Bone Marrow Transplantation. <i>Dermatology</i> , 2000, 201, 80-82.	2.1	14
274	Loss of Heterozygosity on Chromosome 17q in Epithelial Ovarian Tumors: Association with Carcinomas with Serous Differentiation. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 152-157.	1.4	23
275	Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. <i>Cancer</i> , 2000, 88, 2290-2297.	4.1	46
276	Generalized pruritic eruption with suprabasal acantholysis preceding the development of bullous pemphigoid. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 96-98.	1.3	11
277	Burden of myocardial damage in cardiac allograft rejection: Scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 132-139.	2.1	29
278	Genetic, Clinical, And Biochemical Analysis Of Unrelated Spanish Families With Multiple Endocrine Neoplasia Type I. <i>Endocrine Practice</i> , 2000, 6, 13-19.	2.1	4
279	Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. <i>Cancer</i> , 2000, 88, 2290-2297.	4.1	2
280	MEN1 Gene mutation analysis of sporadic adrenocortical lesions. <i>International Journal of Cancer</i> , 1999, 80, 373-379.	5.1	87
281	PCR analysis in the pathological diagnosis of Whipple's disease: emphasis on extraintestinal involvement or atypical morphological features. , 1999, 188, 318-321.		15
282	Mixed Medullary and Follicular Carcinoma of the Thyroid. <i>American Journal of Pathology</i> , 1999, 155, 1413-1418.	3.8	29
283	hMLH1 Promoter Hypermethylation Is an Early Event in Human Endometrial Tumorigenesis. <i>American Journal of Pathology</i> , 1999, 155, 1767-1772.	3.8	280
284	Squamous Cell Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 1999, 18, 191-197.	1.4	61
285	Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. <i>Aids</i> , 1999, 13, 2261-2267.	2.2	207
286	Molecular Pathology of Multiple Endocrine Neoplasia Type I. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 195-204.	2.1	10
287	K-ras mutations in nonmucinous ovarian epithelial tumors. <i>Cancer</i> , 1998, 82, 1088-1095.	4.1	72
288	Sustentacular cells occur frequently in the familial form of medullary thyroid carcinoma. , 1998, 184, 420-423.		16

#	ARTICLE	IF	CITATIONS
289	Molecular pathology of ovarian carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1998, 433, 103-111.	2.8	39
290	Renal cell carcinoma metastatic to the thyroid gland: A comparative molecular study between the primary and the metastatic tumor. <i>Endocrine Pathology</i> , 1998, 9, 255-260.	9.0	9
291	Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1482-1488.	6.4	31
292	A novel germline mutation in exon 5 of the multiple endocrine neoplasia type 1 gene. <i>Journal of Molecular Medicine</i> , 1998, 76, 837-839.	3.9	11
293	Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. <i>Journal of Nuclear Cardiology</i> , 1998, 5, 551-557.	2.1	50
294	Multiple follicular hamartomas with sweat gland and sebaceous differentiation, vermiculate atrophoderma, milia, hypotrichosis, and late development of multiple basal cell carcinomas. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 853-857.	1.2	19
295	Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. <i>Human Pathology</i> , 1998, 29, 1160-1164.	2.0	144
296	Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. <i>Human Pathology</i> , 1998, 29, 840-845.	2.0	124
297	Current Topics in Pathology of Gynecologic Tumors. <i>International Journal of Surgical Pathology</i> , 1998, 6, 121-134.	0.8	2
298	Clinical Forms of Presentation and Evolution of Diffuse Sclerosing Variant of Papillary Carcinoma and Insular Variant of Follicular Carcinoma of the Thyroid. <i>Thyroid</i> , 1998, 8, 385-391.	4.5	72
299	Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2417-2420.	3.6	68
300	Alpha-Inhibin Immunostaining in Diagnostic Pathology. <i>Advances in Anatomic Pathology</i> , 1998, 5, 263.	4.3	19
301	RET Protooncogene Analysis in the Diagnosis of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type II. <i>Advances in Anatomic Pathology</i> , 1998, 5, 196-201.	4.3	12
302	K-ras mutations in nonmucinous ovarian epithelial tumors. <i>Cancer</i> , 1998, 82, 1088-1095.	4.1	12
303	Inhibin A Expression in Adrenal Neoplasms. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 1998, 6, 42-49.	2.0	19
304	Multiple idiopathic mucosal neuromas: A minor form of multiple endocrine neoplasia type 2B or a new entity?. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 349-352.	1.2	36
305	Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial pheochromocytoma. <i>Clinical Endocrinology</i> , 1997, 46, 359-363.	2.4	13
306	Identification of a novel somatic mutation in the RET proto-oncogene in a patient with sporadic medullary thyroid carcinoma. <i>Human Mutation</i> , 1997, 9, 476-476.	2.5	3

#	ARTICLE	IF	CITATIONS
307	K-ras mutations in mucinous ovarian tumors. , 1997, 79, 1581-1586.		200
308	Thyroid Paraganglioma: A Clinicopathologic and Immunohistochemical Study of Three Cases. American Journal of Surgical Pathology, 1997, 21, 748-753.	3.7	95
309	Metastatic Neuroendocrine Tumors to the Thyroid Gland Mimicking Medullary Carcinoma: A Pathologic and Immunohistochemical Study of Six Cases. American Journal of Surgical Pathology, 1997, 21, 754-762.	3.7	71
310	Ras Oncogene Mutations in Thyroid Tumors. Diagnostic Molecular Pathology, 1996, 5, 45-52.	2.1	65
311	Synchronous Mucinous Tumors of the Appendix and the Ovary Associated with Pseudomyxoma Peritonei. American Journal of Surgical Pathology, 1996, 20, 739-746.	3.7	103
312	Mixed Strumal and Mucinous Carcinoid Tumor of the Ovary. International Journal of Gynecological Pathology, 1995, 14, 179-183.	1.4	18
313	Utility of ^{99m} Tc-sestamibi scintigraphy as a first-line imaging procedure in the preoperative evaluation of hyperparathyroidism. Clinical Endocrinology, 1995, 43, 525-530.	2.4	50
314	Analysis ofRET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer, 1995, 76, 479-489.	4.1	145
315	Expression of theret proto-oncogene in phaeochromocytoma. Anin situ hybridization and northern blot study. Journal of Pathology, 1995, 176, 63-68.	4.5	12
316	Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocrine Pathology, 1995, 6, 267-278.	9.0	21
317	Human parathyroid hormone-related protein in ovarian small cell carcinoma. An immunohistochemical study. Cancer, 1994, 73, 1878-1881.	4.1	76
318	Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer, 1994, 74, 1778-1783.	4.1	77
319	Absence of Epstein-Barr Virus DNA in Lymphoepithelioma-like Carcinoma of the Uterine Cervix. American Journal of Clinical Pathology, 1994, 101, 117-117.	0.7	17
320	Biotin-containing Intranuclear Inclusions in Tumor Cells: Possible Cause for Misinterpreting Nuclear Antigen Immunostaining. American Journal of Clinical Pathology, 1994, 102, 706-707.	0.7	7
321	Polysialic Acid of the Neural Cell Adhesion Molecule in the Human Thyroid. American Journal of Surgical Pathology, 1994, 18, 399-411.	3.7	88
322	Adenocarcinoma In Situ of the Uterine Cervix. International Journal of Gynecological Pathology, 1993, 12, 219-223.	1.4	2
323	Desmoplastic Small Round-Cell Tumor. American Journal of Surgical Pathology, 1992, 16, 306.	3.7	46
324	Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer, 1992, 70, 152-160.	4.1	65

#	ARTICLE	IF	CITATIONS
325	Ovarian carcinoma preceded by cerebral metastasis: Review of the literature. <i>Gynecologic Oncology</i> , 1992, 45, 206-210.	1.4	18
326	Rhabdomyosarcomas developing in association with mediastinal germ cell tumours. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992, 420, 539-543.	1.4	25
327	Keratin Expression in Normal Vulva, Non-neoplastic Epithelial Disorders, Vulvar Intraepithelial Neoplasia, and Invasive Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 1991, 10, 341-355.	1.4	11
328	Simultaneous carcinoma involving the endometrium and the ovary. A clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases. <i>Cancer</i> , 1991, 68, 2455-2459.	4.1	69
329	Immunohistochemical study of sarcoma-like mural nodules in a mucinous cystadenocarcinoma of the ovary. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1991, 419, 89-92.	1.4	22
330	Leu-M 1 immunoreactivity in papillary carcinomas of the thyroid gland; microcarcinoma, encapsulated, conventional and diffuse sclerosing subtypes. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1991, 419, 447-448.	1.4	5
331	Cavernous angiomas of the cranial nerves. <i>Journal of Neurosurgery</i> , 1990, 73, 620-622.	1.6	79
332	Ovarian tumors with functioning stroma an immunohistochemical study of 100 cases with human chorionic gonadotropin monoclonal and polyclonal antibodies. <i>Cancer</i> , 1990, 65, 2001-2005.	4.1	42
333	Verrucous Carcinoma of the Vulva. A Clinicopathologic and Immunohistochemical Study of Five Cases. <i>International Journal of Gynecological Pathology</i> , 1989, 8, 1-7.	1.4	38
334	Meningo-Angiomatosis: A case report. <i>British Journal of Neurosurgery</i> , 1988, 2, 97-100.	0.8	6
335	Endomyocardial diagnosis of cardiac lipomatosis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1987, 13, 269-270.	0.3	4